肥胖和/或NAFLD患者的药物性肝损伤

与药物有关的肝毒性是一个严重的健康问题,广泛影响着患者、医疗机构和政府监管机构.另外,由于久坐的生活方式和热量过度摄取,我们还面临着肥胖和非酒精性脂肪性肝病（NAFLD）的流行和困扰,因为肥胖和/或NAFLD提高各种疾病的风险,成为影响公众健康的又一个主要问题,这些患者平均使用药物的量远高于非肥胖患者.越来越多的证据表明,某些药物能够增加肥胖和NAFLD患者药物诱发肝损伤（DILI）的风险.因此,我们应该重视和防治肥胖和NAFLD患者DILI的发生.

Drug-induced Liver Injury in Obesity and Nonalcoholic Fatty Liver Disease

Drug- related hepatotoxicity is a serious health problem, with broad implications for patients, healthcare providers and governmental regulatory agencies. Moreover, we are also facing an epidemic and confuse of obesity and nonalcoholic fatty liver disease （NAFLD）, by a sedentary life style and calorie overconsumption. This poses a major issue for public health since obesity or/and NAFLD primarily enhances the risk of various illnesses, these patients are consuming on aver- age more drugs than non-obese or/and NAFLD individuals. There is growing evidence that obesity and NAFLD patients can increase the risk of drug-induced liver injury （DILI）, at least for some drugs. We should pay attention to prevention and treatment of the occurrence of DILI in obesity and NAFLD patients.